Clinical trials
Completed Nasopharyngeal Carcinoma trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
80 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 80 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 24 |
| Akeso | 3 |
| Fudan University | 3 |
| Guangxi Medical University | 3 |
| Jiangsu HengRui Medicine Co., Ltd. | 3 |
| Xinqiao Hospital of Chongqing | 3 |
| Zhao Chong | 3 |
| Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2 |
| Hong Kong Nasopharyngeal Cancer Study Group Limited | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nasopharyngeal Carcinoma | 80 |
| Nasopharyngeal Neoplasms | 6 |
| Recurrence | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Malnutrition | 2 |
| Neoplasm Metastasis | 2 |
| Stomatitis | 2 |
| Body Weight | 1 |
| Carcinoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Trials
Showing 1 to 25 of 80. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.